BR112021022635A2 - Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 - Google Patents

Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2

Info

Publication number
BR112021022635A2
BR112021022635A2 BR112021022635A BR112021022635A BR112021022635A2 BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2 BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2
Authority
BR
Brazil
Prior art keywords
amino
methylpyrazin
decan
azaspiro
chloropyridin
Prior art date
Application number
BR112021022635A
Other languages
English (en)
Portuguese (pt)
Inventor
Shaoling Li
G Ballmer Steven
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of BR112021022635A2 publication Critical patent/BR112021022635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021022635A 2019-06-07 2020-06-04 Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 BR112021022635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
BR112021022635A2 true BR112021022635A2 (pt) 2022-01-04

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022635A BR112021022635A2 (pt) 2019-06-07 2020-06-04 Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2

Country Status (15)

Country Link
US (2) US11220501B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980128A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022534788A (cg-RX-API-DMAC7.html)
KR (1) KR20220019017A (cg-RX-API-DMAC7.html)
CN (2) CN114190090A (cg-RX-API-DMAC7.html)
AU (1) AU2020288631A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022635A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142430A1 (cg-RX-API-DMAC7.html)
IL (1) IL288568A (cg-RX-API-DMAC7.html)
MA (1) MA56113A (cg-RX-API-DMAC7.html)
MX (1) MX2021014855A (cg-RX-API-DMAC7.html)
PH (1) PH12021552902A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112461QA (cg-RX-API-DMAC7.html)
TW (1) TW202112785A (cg-RX-API-DMAC7.html)
WO (1) WO2020247643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
MA56113A (fr) 2022-04-13
US12528807B2 (en) 2026-01-20
JP2022534788A (ja) 2022-08-03
TW202112785A (zh) 2021-04-01
MX2021014855A (es) 2022-01-18
CN115141205A (zh) 2022-10-04
EP3980128A1 (en) 2022-04-13
IL288568A (en) 2022-02-01
AU2020288631A1 (en) 2021-12-09
JP2025138706A (ja) 2025-09-25
PH12021552902A1 (en) 2022-04-04
US11220501B2 (en) 2022-01-11
CN114190090A (zh) 2022-03-15
WO2020247643A1 (en) 2020-12-10
KR20220019017A (ko) 2022-02-15
CA3142430A1 (en) 2020-12-10
US20210253574A1 (en) 2021-08-19
SG11202112461QA (en) 2021-12-30
US20220298159A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
CR20220251A (es) Nuevos derivados de metilquinazolinona
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BR112021011325A2 (pt) Derivados de rapamicina
WO2019139899A8 (en) Benzamide compounds
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
EP4706761A3 (en) Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
BR112023022050A2 (pt) Agonistas do receptor de orexina e usos destes
EP4321519A3 (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021002529A (es) Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos.
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
PH12021552902A1 (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
AU2018274378A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
BR112021018587A2 (pt) Compostos de heteroaril(heterociclil)metanol úteis no tratamento de hiperglicemia
WO2022104153A3 (en) Compounds and methods for treating viral infections
BR112022017779A2 (pt) Imunomodulação de azaletos de o-het-arila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.